Objective: Aim of the study was to investigate the influence of CSF Aß42, p-tau and t-tau on cognitive functioning. Methods: We analyzed the ability of the CSF biomarkers amyloid ß42, phosphorylated tau181 and total tau to predict the results on a cognitive screening test that assesses multiple cognitive domains (CAMCOG-R) in 65 memory clinic patients (73.1 ± 8.2 years) (n=30 probable Alzheimer's disease (AD), n=7 possible AD, n=12 non-AD dementia, n=16 mild cognitive impairment).
Introduction
Cerebrospinal fluid (CSF) biomarkers amyloid ß42 (Aß42), phosphorylated tau181 (p-tau) and total tau (t-tau) concentrations are altered in Alzheimer's disease (AD) patients compared to controls.
In other types of dementia and also in part of the patients with mild cognitive impairment (MCI), changes in these biomarker concentrations, although less specific, have been reported.1,2,3 Aß is said to be neurotoxic,4 while CSF tau and p-tau are suggested to reflect neurodegeneration.5
Likely, pathological concentrations of these proteins induce or signal neuronal damage, resulting in cognitive impairment.
To date, research on the correlation between CSF biomarkers and cognitive functions, however, shows contradicting results. In AD patients, inconsistent correlations between the Mini
Mental State Examination (MMSE) and Aß42 have been reported.6,7,8,9 A correlation between the MMSE and tau was often lacking,6,7 but sometimes present.9 The MMSE is a cognitive screening test that is easily applicable in clinical practice, but lacks sensitivity and specificity and may be biased by lack of correction for educational level.10,11 This possibly explains these inconsistent results. A more extensive assessment of cognitive functioning may be a more valid approach to study the relation between CSF biomarkers and cognitive functioning. The few studies that have used such an extensive assessment again showed inconsistent results. In AD patients, a weak correlation between a paired-associate memory test and CSF p-tau and t-tau, but not Aß42, has been reported,12 while others failed to find a correlation between the CAMCOG, a cognitive measure that covers multiple domains, and CSF tau.13 In a heterogeneous group of MCI and dementia patients (both AD and non-AD), a correlation was found between false recognition and levels of CSF Aß42, but not t-tau.14 We aimed to investigate the influence of CSF Aß42, p-tau and t-tau concentrations on cognitive functioning. We hypothesized that changes in these CSF biomarkers reflect neuronal damage and directly underlie cognitive impairment. Therefore, we expect a correlation between 1 ). Mean age (± SD) was 73.1 (± 8.2) years.
We used linear regression to examine the relation between CSF biomarkers and the
performance on the CAMCOG-R. As dependent variable we used the CAMCOG-R score, related to the cut-off value, since this cut-off is adjusted for age and education. This relative score was calculated using the following formula: total score/cut-off * 100, and: (non-)memory score * (cut-off/maximum score). Aß42, p-tau181 and t-tau concentrations were not normally distributed and were log-transformed. Analyses were corrected for sex. Primary analyses included the total sample of 65 patients, predicting the CAMCOG-R total score and the scores on the memory and non-memory sections using CSF biomarkers. For secondary analyses, we divided the sample into subgroups based on their biomarker results to increase the likelihood of a neurodegenerative disorder being present. We used previously established cut-off values2 (see table 2) and reran our linear regression models. We did not use the clinical diagnoses for subgroup analyses, since both CAMCOG-R and results of CSF analyses may have influenced the diagnostic decision making, whereas CSF biomarker concentrations are an objective measure and therefore subgroup analyses based on these concentrations are more likely to yield valid results. Figure 1 shows the correlation between each of the CSF biomarkers and the total CAMCOG-R score. In the total sample including all 65 patients, neither CSF Aß42, p-tau181, t-tau, nor the ptau/Aß42 ratio was a significant predictor of the total score on the CAMCOG-R. Using the memory score and non-memory score as dependent variables in the linear regression model did not change these results.
Results
With respect to the secondary analyses, only three models of the 36 models tested showed a statistically significant outcome. First, in the group with an aberrant Aß42 concentration, a higher Aß42 was related to a higher total CAMCOG-R score (B 34.8, p=0.040). Second, in the group with an aberrant p-tau181 concentration, a higher t-tau was related to a lower total CAMCOG-R score (B -24.9, p=0.015). Last, in the group with an aberrant t-tau concentration, a higher t-tau was related to a lower non-memory score (B -5.9, p=0.046). All other secondary analyses (k=33) were not significant (data not shown).
We investigated the correlation between CSF biomarkers and cognitive functioning as measured
with an extensive cognitive screening instrument that covers all major cognitive domains. We did not find such a correlation in a heterogeneous group of patients with cognitive impairment. Secondary analyses in subgroups characterized by abnormal biomarker profiles did not convincingly change this finding.
Our results are in agreement with previous research that reported no correlation between the CAMCOG and CSF tau in AD patients.13 However, we did not replicate previously reported findings between CSF biomarkers and memory function.12,14 Memory function is validly assessed by the memory section of the CAMCOG-R,16 indicating that a correlation, if present, should have
been detected in our study. Moreover, it is remarkable that previous studies found correlations in the same cognitive domain but with different CSF biomarkers. That is, one found a correlation with p-tau and t-tau, but not with Aß42,12 while another found a correlation with Aß42, but not with tau.14 It is difficult to explain this discrepancy; it is unlikely that this discrepancy can be attributed to differences in patient samples -only AD patients, versus a heterogeneous group of MCI and dementia patients, among which AD patients. Furthermore, this cannot explain why we did not find a correlation with Aß42 in our heterogeneous group. In addition, a large number of tests and analyses have been performed in these previous studies that had not been corrected for multiple comparisons. The reported correlations were weak to moderate at best and in one study possibly driven by a cluster of patients with extreme values of p-tau and t-tau.12 Consequently, it is possible that these previous findings are the result of a Type I error (i.e., false positive results). 
Discussion

